On the prevalence of somatic pathology among patients with mental disorders

Abstract

Aim. To determine the medical and statistical features of somatic pathology in patients of a therapeutic district with severe mental disorders. Methods. Conducted was a comparative clinical statistical analysis of data on patients’ referral to outpatient psychiatric health services (924 people, the main group) and patients of one therapeutic district of Naberezhnye-Chelny city (2250 pe-ople, the comparison group) for the year 2010. The method of observation - comprehensive, obtaining the necessary medical and statistical information - copying of the data from the ambulatory patient records. Results. In the structure of the somatic pathology among patients of the therapeutic district (comparison group) according to the referral data the leading position is held by cardiovascular disease (32.2%), diseases of the nervous (24%) and respiratory (21.1%) systems. In the group of patients with mental disorders the leading nosological group were diseases of the nervous system (30.2%) and cardiovascular disease (28.2%). Patients of the main group rarely visited the district physician themselves, most often it occured after the referral of a psychiatrist in order to pass the medical and social assessment, or to obtain medications. Conclusion. Due to the lack of criticism for their own condition, the patients with chronic mental illnesses rarely come to visit physicians of the therapeutic service, thus greater attention to this on behalf of the psychiatrists and other specialists is needed, as well as of the relatives of patients.

Keywords

mental illnesses / patient / somatic pathology / medical care

References

[1] Незнанов Н.Г., Мартынихин И.А., Соколян Н.А., Танянский Д.А. Частота и характер метаболических нарушений у больных шизофренией // Обозр. психиат. и мед. психол. им. В.М. Бехтерева. - 2009. - №2. - C. 17-20.

[2] Barnett A.H., Mackin P., Chaudhry I. et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia // J. Psychopharmacol. - 2007. - Vol. 4 - P. 357-373.

[3] Carney C.P., Jones L., Woolson R.F. Medical comorbidity in women and men with schizophrenia: a population-based controlled study // Department of Internal Medicine: USA. - 2006. - Vol. 21. - P. 1133-1137.

[4] Consensus development conference on antipsychotic drugs and obesity and diabetes // American Diabetes Association, American Psychiatric Association. - 2004. - Vol. 27. - P. 596-601.

[5] Druss B.G., Radford W.D., Rosenheck R.A. et al. Quality of medical care and excess mortality in older patients with mental disorders // Arch. Gen. Psychiatry - 2001. - Vol. 58. - P. 565-572.

[6] Jeste D.V., Gladsjo J.A., Lindamer L.A., Lacro J.P. Medical comorbidity in schizophrenia // Schizophr. Bull. - 1996. - Vol. 22. - P. 413-430.

[7] Osby U., Correia N., Brandt L. et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden // Psych. Res. - 2000. - Vol. 45. - P. 21-28.

[8] McEvoy J., Meyer J., Goff D. et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III // Schizophr. Res. - 2005. - Vol. 80. - P. 19-32.

[9] Parks J., Svendsen D., Foti M.E. et al. Morbidity and mortalityin people with serious mental illness: technical report / National Association of State Mental Health Program Directors. - 2006. - 1482 p.

RIGHTS & PERMISSIONS

Mendelevich B.D., Kuklina A.M.